drugset / Trial / NCT03525782
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
Phase 1/2
Unknown
60 enrolled
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou Anjie Biomedical Technology Co., Ltd. · collabUniversity of Technology, Sydney · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients with advanced non-small cell lung cancer.
Timeline
- Start
- 2018-02-01
- Primary completion
- 2021-01-31
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | — | — |
| Subject | PD-1 knockout | Cell therapy | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |